Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b dose-ranging study of REGN3500 in adults with moderate-to-severe atopic dermatitis
jRCT2080224842Phase 2Terminated
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Aug 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing REGN3500 dose-ranging with Placebo (2 arms). Started Aug 2019; status: terminated.
02
Drugs
itepekimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2080224842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224842.